Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
Adult
Aged
Antiviral Agents
/ administration & dosage
Carcinoma, Hepatocellular
/ epidemiology
Cohort Studies
Female
Follow-Up Studies
Hepatitis B Core Antigens
/ blood
Hepatitis B Surface Antigens
/ blood
Hepatitis B e Antigens
/ blood
Hepatitis B, Chronic
/ complications
Humans
Liver Neoplasms
/ epidemiology
Male
Middle Aged
Predictive Value of Tests
Prospective Studies
Retrospective Studies
Antiviral agents
Hepatitis B core-related antigen
Hepatitis B surface antigen
Hepatocellular carcinoma
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
27
04
2020
accepted:
08
06
2020
pubmed:
20
6
2020
medline:
25
2
2023
entrez:
20
6
2020
Statut:
ppublish
Résumé
Hepatitis B core-related antigen (HBcrAg) is a novel serum viral marker. Recent studies showed that its level correlates with the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to evaluate the accuracy of serum HBsAg and HBcrAg levels at baseline to predict HCC. 1400 CHB patients who received nucleos(t)ide analogues (NA) treatment since December 2005 were included. Their stored serum samples at baseline were retrieved to measure HBsAg and HBcrAg levels. The primary endpoint was the cumulative incidence of HCC. 85 (6.1%) patients developed HCC during a mean (± SD) follow-up duration of 45 ± 20 months. Serum HBcrAg level above 2.9 log10 U/mL at baseline was an independent factor for HCC in hepatitis B e antigen (HBeAg)-negative patients by multivariable analysis (adjusted hazard ratio 2.13, 95% CI 1.10-4.14, P = 0.025). HBcrAg above 2.9 log Serum HBcrAg level predicts the risk of HCC accurately in NA-treated HBeAg-negative CHB patients.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B core-related antigen (HBcrAg) is a novel serum viral marker. Recent studies showed that its level correlates with the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to evaluate the accuracy of serum HBsAg and HBcrAg levels at baseline to predict HCC.
METHODS
METHODS
1400 CHB patients who received nucleos(t)ide analogues (NA) treatment since December 2005 were included. Their stored serum samples at baseline were retrieved to measure HBsAg and HBcrAg levels. The primary endpoint was the cumulative incidence of HCC.
RESULTS
RESULTS
85 (6.1%) patients developed HCC during a mean (± SD) follow-up duration of 45 ± 20 months. Serum HBcrAg level above 2.9 log10 U/mL at baseline was an independent factor for HCC in hepatitis B e antigen (HBeAg)-negative patients by multivariable analysis (adjusted hazard ratio 2.13, 95% CI 1.10-4.14, P = 0.025). HBcrAg above 2.9 log
CONCLUSION
CONCLUSIONS
Serum HBcrAg level predicts the risk of HCC accurately in NA-treated HBeAg-negative CHB patients.
Identifiants
pubmed: 32556643
doi: 10.1007/s00535-020-01700-z
pii: 10.1007/s00535-020-01700-z
doi:
Substances chimiques
Antiviral Agents
0
Hepatitis B Core Antigens
0
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
899-908Subventions
Organisme : Health and Medical Research Fund
ID : 15160551